Value
7.0/10data confidence 83%| Component | Sub-score |
|---|---|
| P/S | 8.0 |
| EV/EBITDA | 6.5 |
| Fwd P/E | 9.4 |
| PEG | 7.3 |
| Analyst target | 4.0 |
- ▸Forward P/E: 9.5x
- ▸PEG: 0.96
- ▸Attractively valued
JAZZ · Why this verdict
Why Jazz Pharmaceuticals (JAZZ) is rated HOLD
Updated
Model-generated analysis — not investment advice. Not a registered investment advisor. Past performance does not guarantee future results.
Show full disclosure ▾Hide full disclosure ▴
About TrendMatrix. TrendMatrix is a publisher of general securities research and market commentary. We publish on a regular schedule. All content is the same for every subscriber in a tier — we do not provide personalized investment advice and we do not take into account any individual subscriber's financial situation, investment objectives, risk tolerance, tax situation, or holdings.
Not investment advice. TrendMatrix is not a registered investment adviser. Our content is for informational and educational purposes only. Consult your own licensed investment adviser, broker, or tax professional before making any investment decision.
Conflicts and positions. The TrendMatrix editorial team frequently holds personal long-term positions in securities discussed. We disclose positions held at the time of publication on each piece. We maintain a trading-window policy: we do not initiate or close positions in the same direction as a TrendMatrix publication within 24 hours before or 72 hours after publication.
No paid promotion. TrendMatrix does not accept payment from any issuer, broker, or third party in exchange for coverage of any security. Our sole compensation is subscription revenue.
No fiduciary duty. No fiduciary, advisory, or agency relationship is created between you and TrendMatrix by reading our content or subscribing to our service.
Performance. Past performance is not indicative of future results. Performance figures reflect the published model only and do not reflect any individual subscriber's actual results.
VerdictHOLD
Overall score6.2/10
ConfidenceMEDIUM
MacroNEUTRAL
Thesis pillars
| Pillar | Expectation | Trend |
|---|---|---|
A put/call ratio of 2.1 indicates that bearish options positioning substantially outpaces bullish activity — the options market is pricing in meaningful downside risk that may reflect institutional concern about a catalyst the fundamental screens do not yet surface. Risk breakdown | Put/call ratio falls below 1.0 over the next 60 days as hedging activity unwinds, removing this overhang from the risk picture. | →Stable |
| CounterElevated put/call ratios in pharmaceutical names frequently represent portfolio hedges by long holders rather than directional bets; the underlying stock's rising on-balance volume suggests buyers continue to accumulate shares even as options hedging increases. | ||
Annual risk filings identify one high-severity and two medium-severity supplier concentration risks — a supply chain fragility that could materially disrupt revenues or margins if a single key relationship is impaired. Bear case | The high-severity supplier concentration risk is resolved or mitigated over the next 12 months, evidenced by removal from or downgrade in the annual risk disclosures. | →Stable |
| CounterThe company's strong free cash flow generation and Piotroski F-Score of 8 out of 9 suggest financial resilience that could absorb a temporary supply disruption better than a lower-quality business, and concentration risk in pharma is often managed through contractual protections not visible in the risk factor language. | ||
The company has beaten earnings estimates in each of the last three quarters with surprises of 36%, 2%, and 39% respectively — a track record of consistent over-delivery that builds confidence in near-term earnings resilience and management's ability to outperform guidance. Earnings | EPS beats continue for at least 2 of the next 4 quarters, with average quarterly surprise remaining above 10%. | →Stable |
| CounterThe quarter preceding the beat streak showed a miss of -32%, demonstrating the business can swing materially; an officer departure or appointment recently filed in regulatory disclosures introduces leadership uncertainty that could break the execution cadence. | ||
Free cash flow substantially exceeds reported net income — a hallmark of pharmaceutical businesses where large non-cash amortization charges depress accounting earnings while actual cash generation remains strong, supporting a higher intrinsic value than reported profits imply. Quality breakdown | Free cash flow continues to exceed reported net income for 2 consecutive quarters, confirming cash generation quality is structural rather than a one-time working capital release. | →Stable |
| CounterA persistent and extreme gap between free cash flow and net income can reflect timing differences or aggressive working capital management rather than genuine economic quality; if amortization charges reverse or cash flow timing normalizes, the gap could compress rapidly. | ||
A put/call ratio of 2.1 indicates that bearish options positioning substantially outpaces bullish activity — the options market is pricing in meaningful downside risk that may reflect institutional concern about a catalyst the fundamental screens do not yet surface.
→StableRisk breakdown
- Expectation
- Put/call ratio falls below 1.0 over the next 60 days as hedging activity unwinds, removing this overhang from the risk picture.
CounterElevated put/call ratios in pharmaceutical names frequently represent portfolio hedges by long holders rather than directional bets; the underlying stock's rising on-balance volume suggests buyers continue to accumulate shares even as options hedging increases.
Annual risk filings identify one high-severity and two medium-severity supplier concentration risks — a supply chain fragility that could materially disrupt revenues or margins if a single key relationship is impaired.
→StableBear case
- Expectation
- The high-severity supplier concentration risk is resolved or mitigated over the next 12 months, evidenced by removal from or downgrade in the annual risk disclosures.
CounterThe company's strong free cash flow generation and Piotroski F-Score of 8 out of 9 suggest financial resilience that could absorb a temporary supply disruption better than a lower-quality business, and concentration risk in pharma is often managed through contractual protections not visible in the risk factor language.
The company has beaten earnings estimates in each of the last three quarters with surprises of 36%, 2%, and 39% respectively — a track record of consistent over-delivery that builds confidence in near-term earnings resilience and management's ability to outperform guidance.
→StableEarnings
- Expectation
- EPS beats continue for at least 2 of the next 4 quarters, with average quarterly surprise remaining above 10%.
CounterThe quarter preceding the beat streak showed a miss of -32%, demonstrating the business can swing materially; an officer departure or appointment recently filed in regulatory disclosures introduces leadership uncertainty that could break the execution cadence.
Free cash flow substantially exceeds reported net income — a hallmark of pharmaceutical businesses where large non-cash amortization charges depress accounting earnings while actual cash generation remains strong, supporting a higher intrinsic value than reported profits imply.
→StableQuality breakdown
- Expectation
- Free cash flow continues to exceed reported net income for 2 consecutive quarters, confirming cash generation quality is structural rather than a one-time working capital release.
CounterA persistent and extreme gap between free cash flow and net income can reflect timing differences or aggressive working capital management rather than genuine economic quality; if amortization charges reverse or cash flow timing normalizes, the gap could compress rapidly.
TrendMatrix Research · core thesis
Engine thesis — one sentence
Jazz Pharmaceuticals has delivered three consecutive earnings beats with large positive surprises and generates free cash flow that substantially exceeds reported net income — a hallmark of high-quality pharmaceutical cash economics — but the stock has reached near-term resistance with only 3.4% upside remaining, an unfavorable 0.6-to-1 risk/reward, an elevated put/call ratio of 2.1 signaling significant hedging activity, and high supply chain concentration risk identified in annual filings.
Falsifiable statement — pillar-level invalidators below. Engine-derived; not personalized advice.
Per-dimension breakdown
Quality
6.5/10data confidence 100%| Component | Sub-score |
|---|---|
| ROE | 0.2 |
| ROA | 4.6 |
| Gross margin | 10.0 |
| Op margin | 9.4 |
| Net margin | 0.3 |
| Current ratio | 7.1 |
| FCF quality | 10.0 |
| Moat | 6.4 |
| Rule of 40 | 8.1 |
| Piotroski F | 8.9 |
- ▸Excellent cash conversion: 1000% FCF/NI
- ▸Rule of 40: 49 (pass)
- ▸Strong Piotroski F-Score: 8/9
Growth
7.3/10data confidence 33%| Component | Sub-score |
|---|---|
| Rev growth | 7.3 |
Momentum
7.4/10data confidence 100%| Component | Sub-score |
|---|---|
| RSI | 5.5 |
| MACD | 10.0 |
| OBV | 10.0 |
| MA position | 9.0 |
| Volume | 2.3 |
- ▸Volume accumulation (rising OBV)
- ▸Above 200-day MA
Sentiment
6.2/10data confidence 100%| Component | Sub-score |
|---|---|
| Analyst rating | 7.5 |
| Price target | 5.8 |
| erm sentiment | 4.9 |
Insider
3.9/10data confidence 75%| Component | Sub-score |
|---|---|
| materiality | 4.5 |
| insider conviction | 2.0 |
| holder change | 5.1 |
- ▸Modest insider selling — $6,228,231 (0.041% of mkt cap)
Peer rank
5.2/10data confidence 80%| Component | Sub-score |
|---|---|
| value rank | 8.8 |
| quality rank | 6.4 |
| growth rank | 5.6 |
- ▸Superior ROE vs peers
Technical
3.8/10data confidence 100%| Component | Sub-score |
|---|---|
| bollinger | 0.1 |
| support resistance | 0.1 |
| 52w position | 10.0 |
| gap | 5.0 |
Risk (lower is worse)
6.3/10data confidence 100%| Component | Sub-score |
|---|---|
| short interest | 6.8 |
| days to cover | 6.3 |
| volatility | 5.9 |
| put call | 9.3 |
| implied vol | 1.4 |
| beta | 10.0 |
| debt equity | 4.6 |
- ▸High IV: 72%
- ▸Concentration risks: 1 HIGH, 2 MED (10-K Item 1A — sized via position_sizing, validated via buy_confidence)
Catalyst
6.2/10data confidence 100%| Component | Sub-score |
|---|---|
| erm | 5.0 |
| earnings history | 6.7 |
| earnings timing | 5.0 |
| surprise avg | 8.1 |
- ▸Strong earnings: 3B/1M
How the verdict was assembled
Engine trigger
Maintain position. Not compelling to add more.
Engine technical detail
verdict_path:
L4:PATH_F_HOLDPassed (6)
- MOMENTUM:7.4>=5.5
- INSIDER:OK
- NEWS_EVENTS:NONE_RECENT
- EARNINGS_PROXIMITY:32d clear
- SEMI_CYCLE_PEAK:CLEAR
- MATERIALS_CYCLE_PEAK:CLEAR
Failed (1)
- ASYMMETRY:-0.5=NEGATIVE
Warning (1)
- 8K_CSUITE_CHANGE:5.02 (officer departure/appointment)
Reward-to-Risk
-0.54
Upside
-5.0%
Downside
9.3%
Sizing output
AVOID
SetupBreakout — Golden cross, above all MAs, RSI 58, MACD bullish
EdgeNo clear edge — No clear edge identified
SuitabilitySpeculative — Binary industry: Biotechnology
Investment implication
None of the engine's positive-conviction paths (C-quality, D-momentum) triggered — the F-path HOLD reflects balanced signals. Strongest-cleared gate: MOMENTUM:7.4>=5.5. Top dim: Momentum at 7.4; weakest: Technical at 3.8. No conviction either direction.
The strongest dimensions are Momentum at 7.4, Growth at 7.3, and Value at 7.0; the weakest are Technical at 3.8, Insider at 3.9, and Peer rank at 5.2. The V9 engine flagged 1 failed gate with 1 warning, producing an asymmetric reward-to-risk of -0.54 and an engine sizing output of AVOID.
What would invalidate the thesis
Falsifying conditions — when triggered, the corresponding pillar's thesis is invalidated.
- P1Three Consecutive Earnings Beats
Trip ifEPS surprise falls below 0% for 2 consecutive quarters.
- P2Exceptional Free Cash Flow Conversion
Trip ifFCF-to-net-income ratio falls below 100% for 2 consecutive quarters, indicating free cash flow no longer exceeds reported earnings.
- P3Elevated Options Market Hedging
Trip ifPut/call ratio falls below 1.0 and sustains for 60 consecutive days, confirming the hedging overhang has cleared.
- P4High Severity Supply Chain Concentration
Trip ifThe count of disclosed high-severity supplier concentration risks falls to 0 in the next annual 10-K or 10-K/A filing.